SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Sarah Cristina Gozzi-SilvaGil BenardRicardo Wesley AlbercaTatiana Mina YendoFranciane Mouradian Emidio TeixeiraLuana de Mendonça OliveiraDanielle Rosa BeserraAnna Julia PietrobonEmily Araujo de OliveiraAnna Cláudia Calvielli Castelo BrancoMilena Mary de Souza AndradeIara Grigoletto FernandesNátalli Zanete PereiraYasmim Álefe Leuzzi RamosJulia Cataldo LimaBruna ProvenciSandrigo ManginiAlberto José da Silva DuarteMaria Notomi SatoPublished in: Tropical medicine and infectious disease (2021)
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a pandemic. SARS-CoV-2 infection can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure. Individuals receiving a heart transplantation (HT) may be at higher risk of adverse outcomes attributable to COVID-19 due to immunosuppressives, as well as concomitant infections that may also influence the prognoses. Herein, we describe the first report of two cases of HT recipients with concomitant infections by SARS-CoV-2, Trypanosoma cruzi, and cytomegalovirus (CMV) dissemination, from the first day of hospitalization due to COVID-19 in the intensive care unit (ICU) until the death of the patients.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- coronavirus disease
- acute respiratory distress syndrome
- mechanical ventilation
- trypanosoma cruzi
- extracorporeal membrane oxygenation
- septic shock
- end stage renal disease
- ejection fraction
- intensive care unit
- newly diagnosed
- chronic kidney disease
- early onset
- replacement therapy
- smoking cessation
- patient reported
- diffuse large b cell lymphoma